Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06427239
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-05-19
Brief Title:
Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Single-center Open-label Exploratory Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is being conducted to evaluate the safety tolerability and efficacy of HRS-4642 combined with adebelimab in subjects with locally advanced or metastatic pancreatic ductal adenocarcinoma
Detailed Description:
This study is an open single center exploratory clinical trial aimed at evaluating the efficacy and safety of HRS-4642 combined with adebelimab in the treatment of patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma
This study experiment is divided into two stages dose exploration stage and efficacy exploration stage During the dose exploration phase RP2D was determined based on the safety tolerability and preliminary efficacy data of HRS-4642 combined with adelbizumab treatment and then entered the efficacy exploration phase
This study experiment is divided into two stages dose exploration stage and efficacy exploration stage During the dose exploration phase RP2D was determined based on the safety tolerability and preliminary efficacy data of HRS-4642 combined with adelbizumab treatment and then entered the efficacy exploration phase
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None